Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 143Gastro-enteropancreatic neuroendocrine tumor 29Carcinoma, Neuroendocrine 18Neoplasms 15Breast Neoplasms 13Adenoma, Islet Cell 13Prostatic Neoplasms 11Carcinoma, Hepatocellular 11Carcinoid Tumor 11Stomach Neoplasms 10Pheochromocytoma 10Pancreatic Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Paraganglioma 9Thyroid Neoplasms 8Neoplasm Metastasis 8Lung Neoplasms 8Cholangiocarcinoma 8Small Cell Lung Carcinoma 7Ovarian Neoplasms 7Melanoma 7Esophageal Neoplasms 7Anus Neoplasms 7Rectal Neoplasms 6Mesothelioma 6Colonic Neoplasms 6Carcinoma 6Brain Neoplasms 6Uterine Cervical Neoplasms 5

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parotid Neoplasms × NET × 1 year × Clear all
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡